{
  "id": "adv_mhgap#management_577f8c3b",
  "content": "differs by type of psychosocial intervention.\nreceiving acamprosate or naltrexone. Education of\nImplementation considerations the individual and their carer (e.g. family member)\ny Both naltrexone and acamprosate are relatively regarding potential adverse events with disulfiram is\nexpensive medicines compared with disulfiram, important. The balance of benefits versus harms in\nwhich is considerably less expensive and may be non-specialized settings is unclear.\nmore readily accessible in low-income settings. y Discontinuities in drug availability and access to\nHowever, medicines may not be registered and psychosocial interventions (common in LMICs) may\navailable in all countries. The decision to use interfere with continuation of treatment and should\nacamprosate, disulfiram or naltrexone should be be considered in planning treatment.\n17\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.2 Anxiety (ANX)\nANX1. In adults with anxiety disorders (excluding social\nanxiety disorder and specific phobias), are antidepressants\n(tricyclic antidepressants [TCAs] and selective serotonin\nreuptake inhibitors [SSRIs]) effective and safe compared with\ntreatment as usual, waitlist, no treatment, or alternative\npsychological or pharmacological treatments?\nRecommendation (new): Selective serotonin reuptake inhibitors (SSRIs) should be considered for\nadults with panic disorder. If SSRIs are not available, consider offering",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "relationships",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General â€” Management differs by type of psychosocial intervention.\nreceiving acamprosate or naltrexone. Education of\nImplementation considerations the individual and their carer (e.g. family member)\ny Both naltrexone and acamprosate are relatively regarding potential adverse events with disulfiram is\nexpensive medicines compared with disulfiram, important. The balance of benefits versus harms in\nwhich is considerably less expensive and may be non-specialized settings is unclear.\nmore readily accessible in low-income settings. y Discontinuities in drug availability and access to\nHowever, medicines may not be registered and psychosocial interventions (common in LMICs) may\navailable in all countries. The decision to use interfere with continuation of treatment and should\nacamprosate, disulfiram or naltrexone should be be considered in planning treatment.\n17\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.2 Anxiety (ANX)\nANX1. In adults with anxiety disorders (excluding social\nanxiety disorder and specific phobias), are antidepressants\n(tricyclic antidepressants [TCAs] and selective serotonin\nreuptake inhibitors [SSRIs]) effective and safe compared with\ntreatment as usual, waitlist, no treatment, or alternative\npsychological or pharmacological treatments?\nRecommendation (new): Selective serotonin reuptake inhibitors (SSRIs) should be considered for\nadults with panic disorder. If SSRIs are not available, consider offering Differs by type of psychosocial intervention. receiving acamprosate or naltrexone."
}